INmune Bio (INMB) Fundamental Analysis: Revenue, Earnings & Valuation

0.61 / 10

Underperform

Fundamentally, INMB scores 0.6/10. Receivables and inventory turnover are modest (25.9, 47.6) but fixed‑asset utilization is low (0.045). Revenue growth appears inflated (257% YoY) while cost of sales is high (70%). Negative asset‑MV and modest PB‑ROE further weaken the outlook.

Analysis Checks(5/10)

Revenue-MV

Value-0.28

Score1/3

Weight67.33%

1M Return5.06%

Total operating revenue (YoY growth rate %)

Value257.14

Score0/3

Weight-27.26%

1M Return-2.75%

Inventory turnover ratio

Value47.57

Score3/3

Weight-7.21%

1M Return-0.67%

Accounts receivable turnover ratio

Value25.89

Score2/3

Weight-7.14%

1M Return-0.65%

PB-ROE

Value0.35

Score0/3

Weight52.21%

1M Return3.80%

Income tax / Total profit (%)

Value-5.52

Score0/3

Weight-16.23%

1M Return-1.54%

Fixed assets turnover ratio

Value0.04

Score2/3

Weight-11.39%

1M Return-1.01%

Interest coverage ratio (EBIT / Interest expense) (%)

Value15.64

Score2/3

Weight-8.06%

1M Return-0.73%

Cost of sales ratio (%)

Value70.30

Score2/3

Weight-7.91%

1M Return-0.74%

Asset-MV

Value-0.48

Score0/3

Weight65.67%

1M Return4.88%

Is INMB fundamentally strong?

INMB scores 0.61/10 on fundamentals and holds a Premium valuation at present. Backed by its -141.52% ROE, -99774.00% net margin, -0.68 P/E ratio, 1.34 P/B ratio, and 4.59% earnings growth, these metrics solidify its Underperform investment rating.